Table 1 Clinical characteristics of the study subjects

Number

74

58

16

20

20

20

Gender (female/male)

55/19

41/17

14/2

17/3

12/8

18/2

Age (years)

50 (20–75)

50 (20–75)

51 (32–69)

41 (14–62)

57 (14–73)

58 (44–70)

Disease durations (years)

0.8 (0.1–12)

0.8 (0.1–12)

0.7 (0.1–4)

3.5 (0.1–15)

2 (0.7–7)

1 (0.1–10)

Active/remission (number)

44/30

35/23

9/7

10/10

10/10

10/10

MYOACT

1.4 (0.7–4.2)

1.4 (0.7–4.2)

1.4 (0.7–2.6)

–

–

–

Muscle enzymes

 CK, uKat/L

59 (12.5–6621)

58 (12.5–6621)

65.1 (21.3–5890.8)

–

–

–

 AST, uKat/L

30.8 (11.2–420.1)

30.8 (12.4–420.1)

29.8 (11.2–227.6)

21.7 (13.5–68.9)

25.1 (13.5–66.3)

17.3 (9.6–45.2)

 ALT, uKat/L

29.9 (6.2–201.8)

31.7 (10.4–201.8)

25.7 (6.2–139)

19 (9.6–152.2)

14.3 (3.6–72.3)

13.4 (4.9–59.9)

 LDH, uKat/L

284 (137–1267)

282.5 (141–1267)

286 (137–767)

–

–

–

Inflammation marker

 CRP, mg/L

3.2 (1–165)

3.8 (1.1–165)

2.5 (1–7.1)

5.1 (1.3–242)

4.1 (1–43.2)

14.1 (1.5–86.5)

 ESR, mm/h

49 (4–120)

53 (4–120)

30 (6–85)

55 (2–120)

54.5 (2–114)

92.5 (33–120)

 C4, mg/L

203.5 (39.6–454)

222 (39.6–454)

185 (102–437)

153 (23.2–365)

188 (108–375)

208 (117–318)

 C3, mg/L

836 (415–1690)

826 (415–1690)

803 (566–955)

704 (81–1210)

795 (411–1410)

1010 (817–1220)

 Neutrophil, × 10⁹/L

4.5 (1.4–15.1)

5.2 (1.4–12.4)

4.7 (1.5–15.1)

4.8 (0.7–11.8)

4.4 (1.8–11.5)

4.5 (1.9–8.6)

 Lymphocyte, × 10⁹/L

1.4 (0.1–4.1)

1.3 (0.1–4.1)

1.4 (0.3–3.7)

1.4 (0.1–2.8)

1.3 (0.6–2.6)

1.6 (0.9–3.1)

 NLR

3.7 (0.7–23)

4.4 (1.3–23)

3.9 (0.8–14)

3.6 (1.2–31)

3.3 (2.1–11.5)

3.0 (1.4–7.9)